Named Trialmap, the app was jointly created by the parties along with patients.
It will help trial participants to effortlessly view data on the trial and receive reminders for appointments and what they might require to do to be prepared for them.
The app will offer patients the chance to give feedback on a real-time basis about their time in the study, permitting researchers to streamline the trials, at present as well as in the future.
It is intended to assure patients that they are valued for taking part in the trial and to boost patient experiences during the studies.
Trialmap is currently being analysed on a trial of Hummingbird Bioscience’s drug, HMBD-001, carried out by the Centre for Drug Development of Cancer Research UK.
Cancer Research UK Centre for Drug Development Clinical Operations and Data Management head Dr Stephen Nabarro said: “Trialmap has the potential to transform the experience of patients enrolled on clinical trials by giving them easy access to key information about their trial and making sure their voices are heard.
“By hearing directly from patients, and using their feedback when designing future clinical trials, we can make key improvements to how they’re run, allowing us to optimise the design of clinical trials and get more new therapeutics to the people who need them.”
More than 40 patient involvement networks and panel members of Cancer Research UK were part of the consultations and user testing conducted earlier this year.
Patients provided positive responses and, based on their feedback, crucial changes were made to the app.
The patient user testing also allowed Stitch to detect modifications that could be done in the app’s future versions such as making use of visual explanations of the trial, and access for carers.